TY - JOUR
T1 - Melanoma in multiple sclerosis treated with natalizumab
T2 - Causal association or coincidence?
AU - Bergamaschi, Roberto
AU - Montomoli, Cristina
PY - 2009/12
Y1 - 2009/12
N2 - We report a relapsing - remitting multiple sclerosis patient who received monthly intravenous natalizumab. After the fifth dose, the patient had a change in a long-standing mole. Ten months later, the mole became ulcerative and was ablated. Histological examination identified a spreading melanoma reaching the lower dermis (Clark level IV). Considering that at the moment the incidence of melanoma is estimable as about 5 per 100,000 multiple sclerosis person-years treated with natalizumab, and that, in the general population, the incidence of melanoma per 100,000 person-years is more than 10, we may speculate that the occurrence of melanoma during natalizumab treatment in multiple sclerosis is purely a coincidence.
AB - We report a relapsing - remitting multiple sclerosis patient who received monthly intravenous natalizumab. After the fifth dose, the patient had a change in a long-standing mole. Ten months later, the mole became ulcerative and was ablated. Histological examination identified a spreading melanoma reaching the lower dermis (Clark level IV). Considering that at the moment the incidence of melanoma is estimable as about 5 per 100,000 multiple sclerosis person-years treated with natalizumab, and that, in the general population, the incidence of melanoma per 100,000 person-years is more than 10, we may speculate that the occurrence of melanoma during natalizumab treatment in multiple sclerosis is purely a coincidence.
KW - Melanoma
KW - Multiple sclerosis
KW - Natalizumab
UR - http://www.scopus.com/inward/record.url?scp=72749090843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72749090843&partnerID=8YFLogxK
U2 - 10.1177/1352458509347154
DO - 10.1177/1352458509347154
M3 - Article
C2 - 20019096
AN - SCOPUS:72749090843
VL - 15
SP - 1532
EP - 1533
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
IS - 12
ER -